Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
Panelist discusses how the DESTINY-Lung02 trial was a dose optimization study where patients with HER2-mutated non–small cell lung cancer (NSCLC) were randomly assigned to a starting dose of 5.4 mg/kg vs 6.4 mg/kg of trastuzumab deruxtecan (T-DXd). DESTINY-Lung03 was a frontline study for HER2 overexpression in NSCLC looking at different combinations of treatment with T-DXd and immunotherapy agents with or without chemotherapy.
EP: 1.Introduction to HER2-Directed Tumor-Agnostic Approaches
EP: 2.HER2 Key Differences and Current Approaches to Biomarker Testing
EP: 3.Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
EP: 4.Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
EP: 5.Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
EP: 6.Future of HER2-Directed Tumor-Agnostic Therapies
Video content above is prompted by the following:
- Review updates and discuss the clinical implications from the following trials:
- DESTINY-Lung02 (Janne PA. 2024 American Society of Clinical Oncology Annual Meeting. Abstract 8543)
- DESTINY-Lung03 part 1 (Planchard D. World Conference on Lung Cancer 2024. Abstract 730)
- Please highlight any other trials of note in NSCLC and share your approach to clinical decision-making.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F555f5be80532573a6654f0b562c43e11aedf99df-1200x857.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.")
